Quarterly Result14 May 2026, 07:52 pm
Alivus Life Sciences: FY26 Revenue ₹25,518 Mn, PAT ₹5,644 Mn
AI Summary
Alivus Life Sciences Ltd. announced audited financial results for the quarter and year ended March 31, 2026. The Board approved these results on May 14, 2026, and recommended a final equity dividend of ₹5 (250%) per share, subject to shareholder approval. For FY26, the company reported revenue from operations of ₹25,518.32 million and a profit after tax of ₹5,644.83 million. The Board meeting commenced at 4.45 p.m. and concluded at 6.15 p.m.
Key Highlights
- Alivus Life Sciences FY26 revenue from operations stood at ₹25,518.32 million.
- The company's profit after tax (PAT) for FY26 was ₹5,644.83 million.
- A final equity dividend of ₹5 (250%) per share was recommended for FY26.
- The Board approved the audited financial results on May 14, 2026.
- Basic EPS for the year ended March 31, 2026, is ₹45.99.
Price Impact
More from GLS